Do You Own this Little-known Smallcap Stock? >> READ MORE
Here are the latest stock price details of India's top Diagnostics stocks. For more detailed updates, check the latest Diagnostics sector results.
SCRIP | BSE PRICE (Rs) | NSE PRICE (Rs) | CHART | MORE INFO |
---|---|---|---|---|
DR. LAL PATHLABS | 2,170.00 -0.12% | 2,174.00 0.16% |
|
More Info ![]() |
KRSNAA DIAGNOSTICS | 539.15 0.06% | 532.00 -1.57% |
|
More Info ![]() |
METROPOLIS HEALTHCARE | 1,405.00 -2.26% | 1,415.00 -1.61% |
|
More Info ![]() |
NIFTY 50 | Not Listed | 15,783.35 -0.42% |
|
More Info ![]() |
S&P BSE SENSEX | 53,026.97 -0.28% | Not Listed |
|
More Info ![]() |
THYROCARE TECHNOLOGIES | 625.00 -0.99% | 629.00 -0.38% |
|
More Info ![]() |
VIJAYA DIAGNOSTIC | 338.90 1.76% | 337.20 1.37% |
|
More Info ![]() |
BSE prices: June 29, 2022 03:32:00 PM NSE prices: June 29, 2022 3:29:59 PM
Within the Diagnostics sector, the top gainers were VIJAYA DIAGNOSTIC (up 1.8%) and KRSNAA DIAGNOSTICS (up 0.1%). On the other hand, METROPOLIS HEALTHCARE (down 2.3%) and THYROCARE TECHNOLOGIES (down 1.0%) were among the top losers.
Meanwhile, the benchmark S&P BSE SENSEX was at 53,027.0 (down 0.3%).
What else is happening in the markets today? Dig in...
After opening deep in the red, Indian share markets recovered most of the losses as the session progressed but still ended on a negative note.
Here's an analysis of the annual report of DR. LAL PATHLABS for 2021-22. It includes a full income statement, balance sheet and cash flow analysis of DR. LAL PATHLABS. Also includes updates on the valuation of DR. LAL PATHLABS.
As the new variant of Covid-19 emerges, keep an eye on these stocks.
It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.
Here's why Divi's Lab's stock fell over 10% in two days.
For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.
More Views on NewsWith India's economic recovery accelerating, these sectors are likely to give multibagger returns in the future.
Constant product innovation, latest technology, strong supply chain etc can all help companies enjoy monopoly like fortunes.
Some sectors have corrected by 50%. Do they merit a look?
This aspect of investing has a very high weightage on your overall returns, but often gets ignored when winning stories are written.
This is how you can tell the market is going to recover.
More